Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcía Martínez, Rafael
dc.contributor.authorSanz Gea, Clara
dc.contributor.authorMartin Riera, Victor
dc.contributor.authorGuerra-Ruiz, Armando
dc.contributor.authorPaciucci Barzanti, Rosanna
dc.contributor.authorFerrer Costa, Roser
dc.contributor.authorRamírez Serra, Clara
dc.date.accessioned2023-05-10T06:47:20Z
dc.date.available2023-05-10T06:47:20Z
dc.date.issued2023-04-18
dc.identifier.citationGarcía Martínez RJ, Sanz Gea C, Martin-Riera V, Raúl A, Ruiz G, Paciucci Barzanti R, et al. Dasatinib-Induced Chylothorax: A Clinical Laboratory’s Perspective. EJIFCC. 2023 Apr 18;34(1):76.
dc.identifier.issn1650-3414
dc.identifier.urihttps://hdl.handle.net/11351/9488
dc.descriptionDasatinib; Pleural effusion chylothorax
dc.description.abstractDasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis of the pleural effusion is crucial for chylothorax diagnosis. We report a case of a 53-year-old male patient presenting a chylothorax after 14 years of dasatinib therapy where the clinical laboratory was key in the diagnosis.
dc.language.isoeng
dc.publisherInternational Federation of Clinical Chemistry and Laboratory Medicine
dc.relation.ispartofseriesEJIFCC;34(1)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectProteïnes quinases - Inhibidors - Efectes secundaris
dc.subjectEmbassament pleural
dc.subject.meshProtein Kinase Inhibitors
dc.subject.mesh/adverse effects
dc.subject.meshChylothorax
dc.subject.mesh/chemically induced
dc.titleDasatinib-induced chylothorax: a clinical laboratory’s perspective
dc.typeinfo:eu-repo/semantics/article
dc.subject.decsinhibidores de proteínas cinasas
dc.subject.decs/efectos adversos
dc.subject.decsquilotórax
dc.subject.decs/inducido químicamente
dc.relation.publishversionhttps://cms.ifcc.org/wp-content/uploads/2023/04/eJIFCC2023Vol34No1pp076-080.pdf
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Martínez RJG] Clinical Analysis Department, Marqués de Valdecilla University Hospital, Santander, Spain. Evidence-Based Laboratory Medicine Commission, Spanish Society of Laboratory Medicine (SEQCML), Barcelona, Spain. [Gea CS, Martin-Riera V, Ruiz ARG, Barzanti RP, Ferrer-Costa R, Ramirez-Serra C] Grup de Recerca de Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid37124659
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record